Lucida Medical

We develop software to help radiologists find cancer, using AI and MRI.
Contact Us

The power of AI and medical imaging to find cancer

Lucida Medical develops software based on artificial intelligence methods (machine learning and image processing) to enable radiologists to find cancer accurately, consistently and quickly using MRI.

Pi™, our first product, is a CE-marked medical device to support the analysis of MRI for prostate cancer diagnosis. Pi™ is available and is entering clinical use in hospitals across Europe and the UK – you can find out more about Somerset NHS Foundation Trust’s use of Pi™. Pi™ can also be obtained through partners including Sectra, Terarecon and Blackford.

Pending FDA approval, Pi™ is not for sale or clinical use in the USA.

We especially welcome contact from investors and healthcare professionals interested in supporting our research, joining clinical studies, or using Pi™.

Find out more at upcoming conferences:

  • 1-5 Dec 2024: RSNA 2024, Chicago, USA – exhibiting
  • 19-22 Sept 2024: ESUR 2024, Lisbon, Portugal – sponsoring and exhibiting
  • 27-29 June 2024: ESUR Prostate MRI 2024, Netherlands – sponsoring and exhibiting
  • 24-26 June 2024: BAUS 2024, Birmingham, UK – exhibiting
  • 10-12 June 2024: UKIO 2024, Liverpool, UK – attending
  • 16-17 May 2024: BSUR 2024, Manchester, UK – sponsoring and exhibiting
  • 3 May 2024: Irish Radiology AI, Dublin, Ireland – sponsoring and exhibiting
  • 7 April 2024: EAU 2024: EAU 2024, Paris, France – oral presentation (N03, 7 Apr, 17.45)
  • 28 Feb-3 March 2024: ECR 2024, Vienna, Austria – exhibiting, oral presentation (Research Stage 4, RPS 605, 28 Feb, 16:30), AI lightning talk (AI Theatre, 29 Feb, 10.00)
  • 23 Feb 2024: RCPSG Prostate Cancer Training and Update Day 2024, Glasgow, UK – sponsoring and exhibiting

Previous events and publications

6 June 2024: Lucida Medical Ltd announces a distribution agreement with Sectra to offer Pi AI technology to help diagnose prostate cancer

Lucida Medical today announced that it has signed a distribution agreement with international medical imaging IT and cybersecurity company Sectra. Through this agreement, the Lucida Pi application for diagnosing prostate cancer from MRI images will be offered through the Sectra Amplifier Marketplace. This greatly expands the availability of Pi to assist healthcare by improving the speed and accuracy of prostate cancer diagnosis. Further information

19 March 2024: Somerset’s NHS pioneers clinical use of AI software to transform prostate cancer diagnosis. Further information

Lucida Medical, University of Cambridge and Hampshire Hospitals join forces to develop Pi to transform the experience of patients living with prostate cancer

Cancer detection company Lucida Medical and leading doctors in Cambridge and Hampshire launch a £1million project to develop precision medicine technology to identify and manage the most common cancer in men

CAMBRIDGE, UK (30 January 2024) – Lucida Medical, the University of Cambridge and Hampshire Hospitals NHS Foundation Trust have been awarded funding by Innovate UK and the Office for Life Sciences to extend the ground-breaking Pi™ software platform to multiple clinical indications.

Already certified to support cancer diagnosis, this £1million programme will enable Pi™ to be used throughout a patient’s journey with prostate cancer, enabling more accurate and less invasive testing by using artificial intelligence (AI) to combine insights from MRI and clinical tests.

Ground-breaking validation of AI for real-world prostate MRI

Dr Aarti Shah, Chief Investigator of the PAIR-1 research study, presented the latest performance results at ECR 2023 in Vienna. This work, in partnership with Hampshire Hospitals NHS Foundation Trust, shows that Pi can be applied to prostate MRI in routine NHS diagnostic pathways across a range of hospitals, MRI scanners and field strengths, with accuracy in line with expert prostate radiology studies.

Get in touch

To find out more, please contact us through:

Our Partners

We collaborate with Cambridge University, we are a partner in the ReIMAGINE prostate imaging trial, are in the process of establishing collaborative partnerships with several UK NHS Trust hospitals to help further develop and validate and test Pi, our AI system for detecting prostate cancer from MRI.